Phase 1 Uveitis Trial, Not Yet Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years old at the time of giving consent
• People who weigh at least 40 kg at the time of giving consent
• People who are able to understand and sign a consent form, and who are willing and able to attend all required visits and procedures
• People diagnosed with active non-infectious uveitis (inflammation inside the eye that is not caused by infection) affecting the middle, back, or whole eye, confirmed by specific eye examination findings
• People currently taking corticosteroids (steroid medicines) at a dose of prednisone 20 mg per day or less (or an equivalent dose of another steroid), on a stable dose for at least 7 days before receiving the trial treatment, and not also taking other immune-suppressing medicines
• People who were previously on certain immune-suppressing or biologic medicines, provided enough time has passed since stopping those medicines as specified in the trial protocol

Who may not be able to join:

• People with any condition that prevents proper examination of both eyes
• People with a significant eye disease (other than uveitis) that could affect their vision
• People with severe diabetic eye disease or significant fluid build-up in the central part of the retina not related to uveitis
• People whose uveitis affects only the front part of the eye (isolated anterior uveitis)
• People whose only sign of uveitis is fluid build-up in the central retina, with no other signs of eye inflammation
• People with age-related macular degeneration or a condition called serpiginous choroidopathy
• People with a form of short-sightedness-related eye degeneration involving abnormal blood vessel growth under the central retina
• People with a confirmed or suspected infectious (infection-caused) form of uveitis
• People with certain conditions that can look like uveitis, such as lymphoma affecting the eye
• People who have recently received certain medicines, including immune-suppressing drugs, targeted biologic therapies, or anti-VEGF treatments, within specific timeframes before the trial treatment (the exact timeframes vary by medicine — confirm with trial site)
• People who have received steroid injections into or around the eye within 8 weeks before the trial treatment, or certain steroid implants within longer specified periods (confirm with trial site for exact timeframes)
• People who have had eye surgery, including glaucoma or retinal surgery, within 90 days before the trial treatment, or a specific type of laser eye procedure within 30 days
• People with certain serious heart conditions, including severe heart failure, significant heart rhythm problems, abnormal heart electrical readings, unstable chest pain in the past 3 months, a heart attack in the past year, or heart bypass surgery in the past year
• People with significantly reduced kidney function, high levels of protein in their urine, or kidney stones causing symptoms within 6 months of screening
• People who are currently breastfeeding, pregnant, planning to become pregnant, or people capable of becoming pregnant who are not willing to use a highly effective form of contraception
• People who have had a severe allergic reaction to fluorescein dye, or who are unwilling to undergo a fluorescein eye scan
• People who have received a live vaccine within 6 weeks before the trial treatment, or who are expected to need one during the study
• People with an active bacterial, viral, fungal, or other infection requiring treatment (infections must be fully resolved before joining)
• People currently on long-term suppressive treatment for a chronic infection, hospitalised for an infection in the past 60 days, or who have recently used intravenous or injected antibiotics or antiviral medicines
• People with a history of certain serious or recurring herpes infections, active tuberculosis, active hepatitis B (unless specific blood test results confirm otherwise — confirm with trial site), detectable hepatitis C virus, HIV infection, or active syphilis
• People who have had major surgery or significant physical trauma within 4 weeks before the trial treatment, or who have major surgery planned during the study
• People who have received a blood transfusion within the past 3 years
• People who have previously received an organ transplant or a bone marrow or stem cell transplant from another person
• People who have received another investigational (experimental) treatment within 28 days before the planned trial treatment (or longer, depending on the medicine), or who have not yet recovered from side effects of a previous experimental treatment
• People whose blood test results show abnormal levels of liver enzymes, bilirubin, white blood cells, haemoglobin, platelets, neutrophils, or lymphocytes as defined by the trial's specific thresholds (confirm with trial site)
• People with a significant history of kidney, liver, lung, or heart problems, or who are currently receiving treatment for such conditions
• People with any serious or uncontrolled illness, psychiatric condition, or other medical situation that, in the treating doctor's opinion, could put them at risk or affect their ability to participate safely or meaningfully
• People already enrolled in another clinical trial or receiving another experimental treatment at the same time

Important: Always verify eligibility with the trial site directly before applying.